Jerome Deval
Research Subjects
Jerome Deval has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Jekle
Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA
1 shared publication - Antitsa D. Stoycheva
Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, CA 94080, USA
1 shared publication - April Kinkade
Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA
1 shared publication - Caroline Williams
Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA
1 shared publication - David B. Smith
Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA
1 shared publication - Francois Gonzalvez
Department of Genetic and Development, INSERM U567/National Center for Scientific Research UMR 8104, Cochin Institut, Paris 750014, France
1 shared publication
Latest Publications
- Open Access
- 13 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16274
Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
Stimulator of interferon genes (STING) agonists have shown potent anti-tumor efficacy in various mouse tumor models and have the potential to overcome resistance to immune checkpoint inhibitors (ICI) by linking the innate and acquired immune systems. First-generation STING agonists are administered intratumorally; however, a systemic delivery route would greatly expand the clinical use of STING agonists. Biochemical and cell-based experiments, as well as syngeneic mouse efficacy models, were used to demonstrate the anti-tumoral activity of ALG-031048, a novel STING agonist. In vitro, ALG-031048 is highly stable in plasma and liver microsomes and is resistant to degradation via phosphodiesterases. The high stability in biological matrices translated to good cellular potency in a HEK 293 STING R232 reporter assay, efficient activation and maturation of primary human dendritic cells and monocytes, as well as long-lasting, antigen-specific anti-tumor activity in up to 90% of animals in the CT26 mouse colon carcinoma model. Significant reductions in tumor growth were observed in two syngeneic mouse tumor models following subcutaneous administration. Combinations of ALG-031048 and ICIs further enhanced the in vivo anti-tumor activity. This initial demonstration of anti-tumor activity after systemic administration of ALG-031048 warrants further investigation, while the combination of systemically administered ALG-031048 with ICIs offers an attractive approach to overcome key limitations of ICIs in the clinic.
- 13 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16274
Open AccessTumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
Stimulator of interferon genes (STING) agonists have shown potent anti-tumor efficacy in various mouse tumor models and have the potential to overcome resistance to immune checkpoint inhibitors (ICI) by linking the innate and acquired immune systems. First-generation STING agonists are administered intratumorally; however, a systemic delivery route would greatly expand the clinical use of STING agonists. Biochemical and cell-based experiments, as well as syngeneic mouse efficacy models, were used to demonstrate the anti-tumoral activity of ALG-031048, a novel STING agonist. In vitro, ALG-031048 is highly stable in plasma and liver microsomes and is resistant to degradation via phosphodiesterases. The high stability in biological matrices translated to good cellular potency in a HEK 293 STING R232 reporter assay, efficient activation and maturation of primary human dendritic cells and monocytes, as well as long-lasting, antigen-specific anti-tumor activity in up to 90% of animals in the CT26 mouse colon carcinoma model. Significant reductions in tumor growth were observed in two syngeneic mouse tumor models following subcutaneous administration. Combinations of ALG-031048 and ICIs further enhanced the in vivo anti-tumor activity. This initial demonstration of anti-tumor activity after systemic administration of ALG-031048 warrants further investigation, while the combination of systemically administered ALG-031048 with ICIs offers an attractive approach to overcome key limitations of ICIs in the clinic.
- 31 May 2011
- Published by Elsevier in Antiviral Research
- Vol. 90 (2) , 93-101
New opportunities in anti-hepatitis C virus drug discovery: Targeting NS4B
- 31 May 2011
- Published by Elsevier in Antiviral Research
- Vol. 90 (2) , 93-101
New opportunities in anti-hepatitis C virus drug discovery: Targeting NS4B